- Company
- CKD-701 demonstrated the validity in phase III trials
- by Chon, Seung-Hyun Jul 14, 2021 06:03am
- Chong Kun Dang announced on the 12th that Lucentis’ biosimilar CKD-701 proved equivalent to the original drug in Phase 3 trials. Chong Kun Dang will apply to the MFDS for CKD-701. Lucentis, sold by Roche and Novatis, is a drug used to treat eye diseases such as wet age-related macular degeneration (AMD) and diabetic retinopathy. Lucentis' an
- Company
- Omipalisib is 200 times more effective than Remdesivir
- by Kim, Jin-Gu Jul 13, 2021 11:09pm
- Attention is focusing on Omipalisib, which was newly discovered by Korean researchers as a candidate material for COVID-19. In particular, as laboratory studies show that candidate substance is more than 200 times more effective than Veklury (Remdesivir), some are optimistic that it will be a "game changer" for the corona crisis. Some p
- Company
- Dong-A ST has received the right of DA-4501 from AbbVie
- by An, Kyung-Jin Jul 13, 2021 11:08pm
- Dong-A ST has received the right of MerTK inhibitor from AbbVie for the first time in five years. Dong-A ST has terminated two large technology export contracts with global pharmaceutical companies. Dong-A ST plans to review new possibilities based on joint research data that has been conducted for the past five years. Starting with biosim
- Policy
- Benefit plan of Keytruda & Tecentriq will be discussed
- by Moon, sung-ho Jul 13, 2021 11:08pm
- Keytruda (Pembrolizumab) and Tecentriq (Atezolizumab) from global pharmaceutical companies are challenging to expand their benefits as primary drugs for lung cancer. According to the pharmaceutical industry and the medical community on the 10th, the HIRA's Cancer Drugs Benefit Apparel Committee will discuss ways to expand the benefits of the
- Company
- Venclexta combo in the spotlight as a new lymphoma Tx option
- by Jul 13, 2021 05:59am
- The treatment landscape for elderly patients with acute myeloid leukemia (AML), which has a 5-year relative survival rate of less than 10%, is changing with the introduction of a new drug that addresses the unmet needs and improves survival rate. AML is one of the most common types of leukemia in adults with a high unmet need in patients
- Company
- “Reimburse Vyndamax, the only hope for amyloidosis”
- by Eo, Yun-Ho Jul 13, 2021 05:59am
- The hATTR Patients Association came forward to call for the reimbursement approval of ‘Vyndamax’ The patient group recently delivered a ‘Statement for the insurance benefit of Vyndamax' to the Ministry of Health and Welfare and the National Health Insurance Services. The move arose among patients with the reimbursement discussions being
- InterView
- MSD "Will care for employees and new drug reimbursement"
- by Eo, Yun-Ho Jul 13, 2021 12:59am
- Apart from its positives and negatives, MSD (known as Merck in the U.S.) is a company apt at ‘adaptation.’ MSD, which first cut its appearance in circulatory, respiratory drugs, and vaccines, became a leader in the field of diabetes in the 2000s with the introduction of its Januvia(sitagliptin), a DPP-4 inhibitor. In 2010, MSD became a
- Company
- Takeda's innovation in Korea
- by Eo, Yun-Ho Jul 12, 2021 06:20pm
- Takeda Korea, which sold off OTC division & DM division, which was the company's symbol. On the occasion of the 10th anniversary of the corporation's launch, constraints have once again confirmed their commitment to pursuing innovation. Marking the 240th anniversary of Takeda Pharmaceutical's headquarters and Korea Takeda's 10th Annivers
- Company
- Byfavo can be prescribed in general hospitals
- by Eo, Yun-Ho Jul 12, 2021 06:19pm
- The anesthetic drug Byfavo can be prescribed at a general hospital. According to related industries, Hana Pharm's Byfavo (Remimazolam Besylate) passed DC of Big 5 general hospitals, including Seoul National University Hospital and Asan Medical Center, and will also be able to be prescribed it at major advanced general hospitals this month.
- Policy
- Evrenzo has been approved in Korea
- by Lee, Tak-Sun Jul 12, 2021 06:11pm
- A new oral drug that can treat anemia, one of the complications of patients with chronic kidney disease, has been approved in Korea. Until now, the standard therapy for treating the disease has been administered with a red blood cell production stimulating injection called EPO (Erythropoietin) or ESA (Erythropoiesis stimulating agent), and at
